Article

Time, Money Worry Healthcare CIOs in Stage 2 Meaningful Use

According to several healthcare CIOs giving testimony yesterday in the District of Columbia, hospitals are pressed for both time and money when it comes to implementing the necessary changes to their EHR systems and clinical workflows.

For eligible hospitals (EHs), the next phase of the EHR Incentive Programs (i.e., Stage 2 Meaningful Use) begins in October. According to several healthcare CIOs giving testimony yesterday in the District of Columbia, hospitals are pressed for both time and money when it comes to implementing the necessary changes to their EHR systems and clinical workflows.

The Implementation Workgroup, a subcommittee of the Health Information Technology Standards Committee (HITSC), held an all-day hearing featuring four panels, two of which dealing with the challenges facing eligible providers preparing for Stage 2 Meaningful Use.

During the third panel of the Implementation and Usability Hearing, a select panel of healthcare CIOs gave testimony in response to questions posed by the HITSC workgroup. Considering the number of mandates and initiatives hospitals are facing in the coming use, a common theme emerged among the panelists: Many hospitals lack both the time and money to keep pace with meaningful use on top of their other responsibilities.

Read the full story: http://bit.ly/13DXJNv

Source: EHR Intelligence

Related Videos
Aditya Bardia, MD,MPH, FASCO, UCLA Health
dr surya bhatt
Video 6 -"Identifying the Most Impactful Disease Areas and Patient Populations for PDTs"
Melissa B. Jones, MD, staff nurse psychiatrist, Michael E. DeBakey VA Medical Center; assistant professor of psychiatry, Baylor College of Medicine
Video 5 - "Dawn of the Age of Adopting PDTs"
Video 5 - "Potential Consequences of Early Diagnosis of Alzheimer Disease"
Video 5 - "Potential Consequences of Early Diagnosis of Alzheimer Disease"
Amit Singal, MD
Migvis Monduy, MD, Nicklaus Children's Hospital
A panel of 4 experts on PDTs
Related Content
CH LogoCenter for Biosimilars Logo